Skip to main content
Newron Pharmaceuticals S.p.A. logo

Newron Pharmaceuticals S.p.A. — Investor Relations & Filings

Ticker · NWRN ISIN · IT0004147952 LEI · 8156002F8C11F80A9740 SW Manufacturing
Filings indexed 135 across all filing types
Latest filing 2026-03-18 Board/Management Inform…
Country IT Italy
Listing SW NWRN

About Newron Pharmaceuticals S.p.A.

https://www.newron.com/

Newron Pharmaceuticals is a biopharmaceutical company focused on the research and development of novel therapies for diseases of the central and peripheral nervous system (CNS) and pain. The company's portfolio includes Xadago® (safinamide), a globally partnered treatment for Parkinson's disease. Its clinical-stage pipeline is centered on CNS disorders, with a key candidate, evenamide, under investigation for the treatment of schizophrenia.

Recent filings

Filing Released Lang Actions
Newron announces nominations to its Board of Directors at upcoming Annual General Meeting
Board/Management Information Classification · 1% confidence The document is a corporate press release announcing nominations for the Board of Directors ahead of an upcoming Annual General Meeting (AGM). It details the departure of current board members and the proposal of new candidates. While it mentions the upcoming AGM, it is not the AGM materials themselves, but rather a management announcement regarding board composition. According to the filing definitions, announcements regarding changes in the board of directors fall under the 'MANG' category.
2026-03-18 English
EQS-News: Newron announces nominations to its Board of Directors at upcoming Annual General Meeting
Board/Management Information Classification · 1% confidence The document is a corporate announcement regarding the nomination of new Board of Directors members for an upcoming Annual General Meeting. It details the departure of current members and the qualifications of the proposed candidates. While it mentions the upcoming AGM, it is not the AGM materials themselves, but rather a press release announcing personnel changes. According to the filing definitions, announcements regarding changes in the company's board of directors are classified as MANG.
2026-03-18 English
EQS-News: Newron gibt Nominierungen für den Verwaltungsrat bei der bevorstehenden Generalversammlung bekannt
Board/Management Information Classification · 1% confidence The document is a corporate news release announcing upcoming changes to the Board of Directors for Newron Pharmaceuticals S.p.A. ahead of their Annual General Meeting. It details the resignation of two members and the nomination of two new candidates. While it mentions the upcoming AGM, it is primarily an announcement regarding management/board composition changes, which falls under the 'MANG' category.
2026-03-18 German
Newron sichert sich bis zu EUR 38 Mio. zur Fortfuhrung des Phase-III-Entwicklungsprogramms von Evenamide
Share Issue/Capital Change Classification · 1% confidence The document is an ad-hoc announcement regarding a capital increase (Kapitalerhöhung) by Newron Pharmaceuticals S.p.A. It details the issuance of new shares to a group of investors to raise up to EUR 38 million for the company's Phase-III development program. Since the document explicitly describes the issuance of new shares and capital measures, it falls under the 'Share Issue/Capital Change' category.
2026-02-16 German
Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
Regulatory Filings Classification · 1% confidence The document is a corporate press release issued by Newron Pharmaceuticals announcing the publication of peer-reviewed clinical data in a scientific journal. It describes the clinical findings of their drug candidate, evenamide, and provides context on its mechanism of action and ongoing clinical trials. As it is a general regulatory announcement regarding company news that does not fit into specific financial reporting categories like earnings releases or annual reports, it is classified as a Regulatory Filing (RNS).
2026-02-03 English
EQS-News: Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
Regulatory Filings Classification · 1% confidence The document is a press release issued by Newron Pharmaceuticals announcing the publication of peer-reviewed clinical data regarding their drug candidate, evenamide. It provides scientific context, clinical trial results, and forward-looking statements regarding their development program. As it is a general corporate announcement regarding company news (scientific publication) that does not fit into specific financial reporting categories like 10-K, ER, or IR, it is classified as a Regulatory Filing (RNS).
2026-02-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.